Free Trial
NYSE:ZTS

Zoetis (ZTS) Stock Price, News & Analysis

$189.23
+2.64 (+1.41%)
(As of 09/6/2024 ET)
Today's Range
$187.06
$190.44
50-Day Range
$172.58
$189.20
52-Week Range
$144.80
$201.92
Volume
2.71 million shs
Average Volume
2.66 million shs
Market Capitalization
$85.73 billion
P/E Ratio
36.46
Dividend Yield
0.91%
Price Target
$217.11

Zoetis MarketRank™ Stock Analysis

Analyst Rating
Buy
3.11 Rating Score
Upside/​Downside
14.7% Upside
$217.11 Price Target
Short Interest
Healthy
0.90% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.93mentions of Zoetis in the last 14 days
Based on 15 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.93%
From $5.84 to $6.42 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.58 out of 5 stars

Medical Sector

79th out of 910 stocks

Pharmaceutical Preparations Industry

30th out of 426 stocks

ZTS stock logo

About Zoetis Stock (NYSE:ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

ZTS Stock Price History

ZTS Stock News Headlines

Dog and cat best friends playing together outdoors. Lying on the back together
Which Pet Stock Should Get Your Tail Wagging in 2024? (ZTS)
ZTS stock and CHWY stock have different investment cases, but here's what investors may want to consider before buying either of these pet stocks
Q1 2025 EPS Estimates for Zoetis Inc. (NYSE:ZTS) Increased by Analyst
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
Jim Cramer on Zoetis Inc. (ZTS): ‘I Like It Very Much’
3 Pet Care Stocks With Tail-Wagging Potential
Stifel Nicolaus Reiterates "Buy" Rating for Zoetis (NYSE:ZTS)
Biden’s Capital Gains Tax to Devastate Savings!
Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.
Stifel Nicolaus Reaffirms Their Buy Rating on Zoetis (ZTS)
ZTS Apr 2025 155.000 put
ZTS Sep 2024 155.000 call (ZTS240920C00155000)
ZTS Sep 2024 105.000 put (ZTS240920P00105000)
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/4 Dividend
7/18/2024
Last Earnings
8/06/2024
Dividend Payable
9/04/2024
Today
9/07/2024
Next Earnings (Estimated)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
98978V10
Employees
14,100
Year Founded
2012

Price Target and Rating

Average Stock Price Target
$217.11
High Stock Price Target
$237.00
Low Stock Price Target
$196.00
Potential Upside/Downside
+14.7%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$2.34 billion
Pretax Margin
32.46%

Debt

Sales & Book Value

Annual Sales
$8.54 billion
Cash Flow
$6.49 per share
Book Value
$10.95 per share

Miscellaneous

Free Float
455,565,000
Market Cap
$85.73 billion
Optionable
Optionable
Beta
0.88

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. has shown consistent growth in revenue and earnings over recent quarters, indicating a strong financial performance.
  • Positive analyst ratings and price target upgrades from reputable firms like BTIG Research and Piper Sandler suggest a favorable outlook for the stock.
  • Recent price performance shows stability and potential for growth, with the stock trading at $182.86 as of today.
  • Zoetis Inc.'s focus on animal health medicines, vaccines, and diagnostic products positions it well in a growing market with increasing demand for pet care.
  • The company's strong return on equity of 50.67% reflects efficient use of shareholder funds to generate profits.

Cons

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • While Zoetis Inc. has a strong market position, competition in the animal health industry is intensifying, which could impact the company's market share and margins.
  • The stock's current price-to-earnings ratio of 35.24 may be considered high by some investors, potentially limiting immediate upside potential.
  • Market volatility and regulatory changes in the healthcare sector could affect Zoetis Inc.'s operations and financial performance.
  • Debt-to-equity ratio of 1.32 indicates the company relies on debt financing, which could pose risks in case of economic downturns or rising interest rates.
  • Investors should consider the potential impact of any adverse events related to product recalls or regulatory issues on Zoetis Inc.'s stock price and reputation.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 4, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

ZTS Stock Analysis - Frequently Asked Questions

How have ZTS shares performed this year?

Zoetis' stock was trading at $197.37 at the beginning of the year. Since then, ZTS shares have decreased by 4.1% and is now trading at $189.23.
View the best growth stocks for 2024 here
.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) released its quarterly earnings data on Tuesday, August, 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The company's quarterly revenue was up 8.3% on a year-over-year basis.
Read the conference call transcript
.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

Does Zoetis have any subsidiaries?

Zoetis subsidiaries include Jorox Pty, Virtual Recall, Fish Vet Group, Performance Livestock Analytics, Ethos Diagnostic Science, ZNLabs, Phoenix Lab, and more.

Who are Zoetis' major shareholders?

Zoetis' top institutional investors include Bank of New York Mellon Corp (1.03%), Unisphere Establishment (0.98%), Legal & General Group Plc (0.92%) and Clearbridge Investments LLC (0.67%). Insiders that own company stock include Kristin C Peck, Heidi C Chen, Roxanne Lagano, Willie M Reed, Robert J Polzer, Glenn David, Roman Trawicki and Gregory Norden.
View institutional ownership trends
.

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zoetis investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH).

This page (NYSE:ZTS) was last updated on 9/7/2024 by MarketBeat.com Staff

From Our Partners